1Buck M, Garcia-Tsao G, Groszmann R J, et al. Novel Inflammatory Bi- omarkers of Portal Pressure in Compensated Cirrhosis Patients [ J ]. Hepatology ,2014,59 ( 3 ) : 1052 - 1059.
2Kropf J, Gressner AM, Tittor W. Logistic-regression model for assess- ing portal hypertension by measuring hyaluronic acid (hyaluronan) and laminin in serum [J]. Clin Chem, 1991,37 ( 1 ) : 30 - 35.
3Leeming DJ, Karsdal MA, Byrjalsen I, et al. Novel serological neo- epitope markers of extracellular matrix proteins for the detection of portal hypertension [ J ]. Aliment Pharmacol Ther,2013,38 (9) : 1086 - 1096.
4Thabut D, Imbert-Bismut F, Cazals-Hatem D, et al. Relationship be- tween the Fibrotest and portal hypertension in patients with liver dis- ease [J]. Afiment Pharmacol Ther,2007,26 (3) :359 - 368.
5Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C [ J]. Hepatology ,2003,38 ( 2 ) :518 - 526.
6Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4 : an inexpensive and accurate marker of fibrosis in HCV infection, comparison with liver biopsy and fibrotest [J].Hepatology ,2007,46 ( 1 ) : 32 - 36.
7Lisotti A, Azzaroli F, Buonfiglioli F, et al. Indocyanine green retention test as a non-invasive marker of portal hypertension and esophageal varices in compensated liver cirrhosis [J]. Hepatology, 2014,59 ( 2 ) : 643 - 650.
8Iranmanesh P,Vazquez O, Terraz S, et al. Accurate computed tomo- graphy-based portal pressure assessment in patients with hepatocellu- lar carcinoma[J]. J Hepato1,2014,60 (5) :969 - 974.
9Lee JY, Kim TY, Jeong WK, et al. Clinically severe portal hyperten- sion:role of multi-detector row CT features in diagnosis [ J ]. Dig Dis Sci,2014,59(9) :2333 -2343.
